Artículo
Use of nicergoline as adjunctive treatment of neurotrophic keratitis in routine clinical practice: a case series
Autor/es | Miguel-Escuder, L.
Rocha de Lossada, Carlos ![]() ![]() ![]() ![]() ![]() Sabater Cruz, Noelia Sánchez González, José María ![]() ![]() ![]() ![]() ![]() ![]() ![]() Spencer, Felipe Marín-Martínez, Sara Batlle-Ferrando, S. Carreras Castañer, X. Torras, J. Peraza-Nieves, Jorge |
Departamento | Universidad de Sevilla. Departamento de Física de la Materia Condensada |
Fecha de publicación | 2022 |
Fecha de depósito | 2024-06-10 |
Publicado en |
|
Resumen | Purpose: To describe the effectiveness and safety of nicergoline in patients with epithelial corneal defect or corneal ulcer due to neurotrophic keratitis. Methods: A prospective case series review was performed in 14 ... Purpose: To describe the effectiveness and safety of nicergoline in patients with epithelial corneal defect or corneal ulcer due to neurotrophic keratitis. Methods: A prospective case series review was performed in 14 patients (14 eyes) with neurotrophic keratopathy who started treatment with nicergoline as an off-label prescription from January to November of 2020. Patients with a epithelial defect or corneal ulcer due to neurotrophic keratitis were treated with 10 mg of oral nicergoline twice daily. Results/Serial cases: Complete corneal healing was observed in 10 (71.4%) of the 14 patients after 25.6 ± 26.60 days (range 7-90) with nicergoline. In three (21.5%) patients the wound healing was not achieved (all of them with autoimmune disease), and one patient (7.1%) was lost to follow-up. Eleven patients (79%) were females; the average age at consultation was 69 years (44-96). The mean time between diagnosis and the starting of nicergoline was 10.92 ± 8.85 days (0-28). No adverse effects of nicergoline were observed in any subject. Conclusion: Nicergoline as an adjunctive treatment for neurotrophic keratitis showed a potential use in the healing of epithelial defect with a good tolerance in real-life clinical practice. Introduction: |
Cita | Miguel-Escuder, L., Rocha de Lossada, C., Sabater Cruz, N., Sánchez González, J.M., Spencer, F., Marín-Martínez, S.,...,Peraza-Nieves, J. (2022). Use of nicergoline as adjunctive treatment of neurotrophic keratitis in routine clinical practice: a case series. Ocular Immunology and Inflammation, 30 (7-8), 1926-1930. https://doi.org/10.1080/09273948.2021.1976214. |
Ficheros | Tamaño | Formato | Ver | Descripción |
---|---|---|---|---|
Use of nicergoline_Sánchez ... | 399.5Kb | ![]() | Ver/ | Versión aceptada |